Search research articles
Contact Us
Filters
Showing results (81-90 of 107) with videos related to
Page
of 11
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 29, 2025
Prognostic significance and accuracy of oncologists' estimates of survival time in recurrent ovarian cancer
Sharon H Nahm, Belinda E Kiely, Rachel L O'Connell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 28, 2022
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
Yeh Chen Lee, Madeleine T King, Rachel L O'Connell, et al.
Journal of Medical Genetics
|
December 4, 2020
Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in <i>BRCA1/2</i>: results of the observational AGO-TR1 study (NCT02222883)
Jan Hauke, Philipp Harter, Corinna Ernst, et al.
Gynecologic Oncology
|
June 19, 2022
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer
Rachel Campbell, Daniel S J Costa, Martin R Stockler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2016
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer
Joyce F Liu, Isabelle Ray-Coquard, Frederic Selle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2019
Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer
Florian Heitz, Stefan Kommoss, Roshan Tourani, et al.
The Lancet. Oncology
|
November 23, 2015
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Andreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, et al.
The New England Journal of Medicine
|
February 28, 2019
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
Philipp Harter, Jalid Sehouli, Domenica Lorusso, et al.
Cancers
|
March 10, 2022
Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial
Jean-David Fumet, Emilie Lardenois, Isabelle Ray-Coquard, et al.
The Lancet. Oncology
|
May 3, 2025
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial
Sherko Kuemmel, Monika Graeser, Peter Schmid, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 107) with videos related to
Sort By:
Page
of 11
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 29, 2025
Prognostic significance and accuracy of oncologists' estimates of survival time in recurrent ovarian cancer
Sharon H Nahm, Belinda E Kiely, Rachel L O'Connell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 28, 2022
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
Yeh Chen Lee, Madeleine T King, Rachel L O'Connell, et al.
Journal of Medical Genetics
|
December 4, 2020
Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in <i>BRCA1/2</i>: results of the observational AGO-TR1 study (NCT02222883)
Jan Hauke, Philipp Harter, Corinna Ernst, et al.
Gynecologic Oncology
|
June 19, 2022
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer
Rachel Campbell, Daniel S J Costa, Martin R Stockler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2016
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer
Joyce F Liu, Isabelle Ray-Coquard, Frederic Selle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2019
Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer
Florian Heitz, Stefan Kommoss, Roshan Tourani, et al.
The Lancet. Oncology
|
November 23, 2015
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Andreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, et al.
The New England Journal of Medicine
|
February 28, 2019
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
Philipp Harter, Jalid Sehouli, Domenica Lorusso, et al.
Cancers
|
March 10, 2022
Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial
Jean-David Fumet, Emilie Lardenois, Isabelle Ray-Coquard, et al.
The Lancet. Oncology
|
May 3, 2025
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial
Sherko Kuemmel, Monika Graeser, Peter Schmid, et al.
Page
of 11